James Engelhart - 10 Dec 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Role: Chief Financial Officer
Signature: /s/ James Engelhart
Issuer symbol: N/A
Transactions as of: 10 Dec 2021
Net transactions value: -$3,589,146
Form type: 4
Filing time: 10 Dec 2021, 19:43:44 UTC
Previous filing: 26 Nov 2021
Next filing: 07 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BHVN	Common Shares	Options Exercise	$0	+35,000	+313%	$0.000000	46,196	10 Dec 2021	Direct	F1
transaction	BHVN	Common Shares	Sale	$1,033,467	-10,131	-22%	$102.01^*	36,065	10 Dec 2021	Direct	F1, F2
transaction	BHVN	Common Shares	Sale	$2,412,162	-23,487	-65%	$102.70^*	12,578	10 Dec 2021	Direct	F1, F3
transaction	BHVN	Common Shares	Sale	$143,516	-1,382	-11%	$103.85^*	11,196	10 Dec 2021	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BHVN	Employee Stock Option (Right to Buy)	Options Exercise	$0	-35,000	-29%	$0.000000	83,792	10 Dec 2021	Common Shares	35,000	$9.29	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.30 - $102.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.30 - $103.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.31 - $104.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F5	The shares underlying this option vested as to 50% of the shares on January 31, 2017, the grant date, and the remainder vested in 2 equal installments on the first and second anniversaries of the grant date.